VYNE Stock Summary and Trading Ideas (Vyne Therapeutics | NASDAQ:VYNE)

VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.

Vyne Therapeutics trades on the NASDAQ stock market under the symbol VYNE.

As of April 17, 2026, VYNE stock price declined to $0.61 with 181,569 million shares trading.

VYNE has a beta of 3.33, meaning it tends to be more sensitive to market movements. VYNE has a correlation of 0.07 to the broad based SPY ETF.

VYNE has a market cap of $20.30 million. This is considered a Sub-Micro Cap stock.

Last quarter Vyne Therapeutics reported $130,000 in Revenue and -$.12 earnings per share. This fell short of revenue expectation by $-70,000 and exceeded earnings estimates by $.07.

In the last 3 years, VYNE traded as high as $8.73 and as low as $.28.

The top ETF exchange traded funds that VYNE belongs to (by Net Assets): VXF.

VYNE has underperformed the market in the last year with a price return of -66.2% while the SPY ETF gained +36.4%. However, in the short term, VYNE had mixed performance relative to the market. It has outperformed in the last 3 months, returning +7.6% vs +2.8% return in SPY. But in the last 2 weeks, VYNE shares have been beat by the market, returning +1.5% compared to an SPY return of +8.2%.

VYNE support price is $.60 and resistance is $.64 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VYNE shares will trade within this expected range on the day.